Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

191 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A long-term follow-up cohort study of patients that were assigned in two previous studies to compare the clinical results of sclerotherapy of telangiectasias and reticular veins of lower limbs using 0.2% polidocanol diluted in 70% hypertonic glucose (PDHG) vs 75% hypertonic glucose (HG) alone.

All women, previously treated as aforementioned, were invited to be reevaluated regarding late maintenance and pigmentation over two years of follow-up.

No new treatments were applied to the cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polidocanol Versus Glucose Treatment of Telangiectasia Trial

NCT02657252

Varicose Veins Telangiectasis

COMPLETED PHASE4

Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins

NCT02054325

Varicose Veins

COMPLETED PHASE4

Treatment of Leg Telangiectasias With Nd:YAG 1064nm

NCT01118390

Telangiectasias

UNKNOWN NA

Laser Treatment Of Leg Telangiectasias

NCT04004728

Leg Veins

COMPLETED NA

Investigation Into the Pathophysiology and Treatment of Varicose Veins

NCT06192472

Varicose Veins

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Telangiectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telangiectasias Group - Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Previously treated with PDHG, no new interventions were performed.

Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Intervention Type PROCEDURE

Patients previously treated were reassessed for long-term follow-up.

Telangiectasias Group - Hypertonic Glucose 75% (HG)

Previously treated with HG, no new interventions were performed.

No interventions assigned to this group

Reticular Veins Group (PG3T) - Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Previously treated with PDHG, no new interventions were performed.

Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Intervention Type PROCEDURE

Patients previously treated were reassessed for long-term follow-up.

Reticular Veins Group (PG3T) - Hypertonic Glucose 75% (HG)

Previously treated with HG, no new interventions were performed.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Patients previously treated were reassessed for long-term follow-up.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hypertonic Glucose 75% (HG)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients that concluded the participation of 60 days in both primary studies were invited to reevaluate the actual status of treatment (maintenance of treated vessels) and late complications (pigmentation and matting).

Exclusion Criteria

* Patients who did not agree to be reassessed;
* Patients who were not found after all available forms of contact had been tried;
* Patients who went through any kind of intervention on the area of interest in lower limbs between the end of the intervention and the reevaluation for long-term follow-up.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No